Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) (IBeTA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00997191 |
Recruitment Status :
Completed
First Posted : October 19, 2009
Last Update Posted : March 4, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetic Macular Edema | Procedure: Laser photocoagulation Drug: Intravitreal triamcinolone Drug: Intravitreal bevacizumab | Phase 3 |
Macular edema is a leading cause of decreased visual acuity in patients with diabetic retinopathy1,2.
Laser photocoagulation is the standard of care treatment for diabetic macular edema, based on ETDRS and recent clinical trials findings3,4. However, because visual acuity improvement post-laser is observed infrequently, and because of the frequent recurrence or persistence of DME (refractory DME) after appropriate laser treatment, particularly in eyes presenting with angiographically diffuse macular edema5-9, there is a need for alternative treatments for the management of DME. In addition, for some patients with significant cataract, precise visualization of posterior pole structures may not be possible, so that pharmacological therapy with intravitreal agents may be preferable over laser treatment.
Recent studies have shown promising results of pharmacological therapies for Diabetic macular edema. Triamcinolone has shown similar results when compared to ranibizumab and deferred focal/grid LASER in pseudophakic eyes (DRCRnet, prompt versus deferred). Ranibizumab associated with deferred LASER or as monotherapy has also shown promising results (RISE and RIDE). However, there are several concerns regarding long-term intravitreal injections therapies that include economic feasibility for the public health system, risk of endophthalmitis and patient acceptability. For these reasons, the present study decided to check associations between LASER and drug therapy, in an attempt to improve focal/grid laser outcomes with reduced number of intravitreal injections.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) |
Study Start Date : | October 2009 |
Actual Primary Completion Date : | November 2011 |
Actual Study Completion Date : | November 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Laser Group
Focal / grid Laser photocoagulation in diabetic macular edema
|
Procedure: Laser photocoagulation
Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines |
Experimental: Triamcinolone group
Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
|
Drug: Intravitreal triamcinolone
Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
Other Name: Triancinolona (Ophthalmos) |
Experimental: Bevacizumab group
Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
|
Drug: Intravitreal bevacizumab
Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
Other Name: Avastin |
- Best Corrected Visual acuity [ Time Frame: One Year ]
- Macular Mapping Test [ Time Frame: One Year ]
- Multifocal Electroretinogram [ Time Frame: One Year ]
- Central Macular Thickness [ Time Frame: One Year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically significant DME - by biomicroscopic evaluation with generalized breakdown of the inner blood-retina barrier with diffuse fluorescein leakage involving the foveal center and most of the macular area on fluorescein angiography
- Snellen logarithm of minimum angle of 20/40 or worse
- Central macular thickness greater than 275 µm on optical coherence tomography (OCT)
Exclusion Criteria:
- Glycosylated hemoglobin rate above 10%
- History of glaucoma or ocular hypertension
- Systemic corticoid therapy
- History of thromboembolic event (including myocardial infarction or cerebral vascular accident)
- Major surgery within the prior 6 months or planned within the next 28 days
- Uncontrolled hypertension
- Severe systemic disease
- Any condition affecting documentation or follow-up

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997191
Brazil | |
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto | |
Ribeirão Preto, São Paulo, Brazil |
Study Chair: | Maria L Paccola, MD | HC FMRP - USP | |
Study Chair: | André M V Messias, PhD | HCFMRP - USP | |
Study Director: | Bianka Y N Y Katayama, MD | HC FMRP - USP | |
Principal Investigator: | Rodrigo Jorge, PhD | HC FMRP - USP | |
Study Chair: | Rogério A Costa, PhD | HC FMRP - USP |
Responsible Party: | Rodrigo Jorge, Professor, University of Sao Paulo |
ClinicalTrials.gov Identifier: | NCT00997191 |
Other Study ID Numbers: |
6826/2009 |
First Posted: | October 19, 2009 Key Record Dates |
Last Update Posted: | March 4, 2013 |
Last Verified: | February 2013 |
Bevacizumab Diabetes Intravitreal |
Macular edema triamcinolone VEGF |
Macular Edema Edema Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Triamcinolone Bevacizumab Antineoplastic Agents, Immunological Antineoplastic Agents |
Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |